Price$5.05-0.62 (-10.93%)
01:30 PM08:00 PM
News · 26 weeks48+167%
2025-12-142026-06-07
Mix3490d
- Other14(41%)
- SEC Filings9(26%)
- Insider7(21%)
- Earnings4(12%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.SCHEDULE 13G - Co-Diagnostics, Inc. (0001692415) (Subject)
- PRCo-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform CapabilitiesDual-assay strategy designed to support outbreak response and surveillance efforts in affected regionsPotential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of-care platform capabilitiesSALT LAKE CITY, June 2, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics Pvt. Ltd. ("CoSara" or the "JV"). The program includes development of both a pan-Ebola assay designed to rapidly detect multiple ebolavirus sp
- SECSEC Form EFFECT filed by Co-Diagnostics Inc.EFFECT - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECSEC Form S-3 filed by Co-Diagnostics Inc.S-3 - Co-Diagnostics, Inc. (0001692415) (Filer)
- INSIDERChief Executive Officer Egan Dwight H was granted 4,584 shares and returned $8,279 worth of shares to the company (1,633 units at $5.07), increasing direct ownership by 12% to 27,893 units (SEC Form 4) (withholding tax)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERChief Financial Officer Brown Brian Lee was granted 3,750 shares and returned $6,844 worth of shares to the company (1,350 units at $5.07), increasing direct ownership by 12% to 22,379 units (SEC Form 4) to cover taxes4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERPresident Abbott Richard David was granted 1,890 shares and returned $3,448 worth of shares to the company (680 units at $5.07), increasing direct ownership by 55% to 3,417 units (SEC Form 4) (withholding obligation)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERDirector Murphy Edward L. was granted 1,695 shares, increasing direct ownership by 18% to 11,084 units (SEC Form 4)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERDirector Serbin Richard S was granted 1,695 shares, increasing direct ownership by 19% to 10,751 units (SEC Form 4)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERDirector Durenard Eugene was granted 1,695 shares, increasing direct ownership by 19% to 10,668 units (SEC Form 4)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- INSIDERDirector Nelson James B was granted 1,695 shares, increasing direct ownership by 19% to 10,668 units (SEC Form 4)4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- PRCo-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSaraJoint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globallySALT LAKE CITY, May 26, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has advanced the PCR assay development strategy for the Bundibugyo virus ("BDBV") currently causing an outbreak of Ebola disease in the Democratic Republic of the Congo ("DRC") and Uganda, with the support of CoSara Diagnostics Pvt. Ltd. ("CoSara" or the "JV"), the Indian joint venture between Co-Dx and Amb
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesSALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into a securities purchase agreement with certain institutional investors to sell an aggregate of 1,647,447 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 3,294,894 shares of common stock, in a private placement priced at-the-market under Nasdaq rules (the "Offering"). The combined effective offering price for each share of common stock (or pre-funded warrant in-li
- PRCo-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak AlertRecent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platformFollows outbreak of Ebola and WHO emergency declaration, and enhanced CDC traveler screening measuresSALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has completed the assay development strategy for the Bundibugyo virus ("BDBV") currently causing an outbreak of Ebola disease in the Democratic Republic of the Congo and Uganda.
- SECSEC Form EFFECT filed by Co-Diagnostics Inc.EFFECT - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECSEC Form 10-Q filed by Co-Diagnostics Inc.10-Q - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Reports First Quarter 2026 Financial ResultsAdvancing Global Commercialization Through CoSara Regulatory Progress and Regional ExpansionExecuting Clinical Strategy with Upper Respiratory Submission Preparation and TB Study InitiationExpanding International Presence and Reinforcing Platform Differentiation Through Partnerships and IPSALT LAKE CITY, May 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the first quarter ended March 31, 2026.
- SECSEC Form S-3 filed by Co-Diagnostics Inc.S-3 - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial CityLease execution highlights transition from approval to development and advances localized manufacturing strategy in the Kingdom of Saudi Arabia in accordance with Vision 2030SALT LAKE CITY, May 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture, CoMira Diagnostics LLC ("CoMira"), has finalized a lease agreement for its planned manufacturing facility in Sudair Industrial City in the Kingdom of Saudi Arabia ("KSA").
- PRCo-Diagnostics Announces First Quarter 2026 Earnings Release Date and WebcastSALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its first quarter 2026 financial results on Thursday, May 14, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
- PRCo-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership, U.S. Department of State, and global stakeholdersSALT LAKE CITY, April 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate in the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026. The Company will present the Co-Dx Mycobacterium tuberculosis ("MTB" or "TB") test on the Co-Dx PCR platform* during a roundtable discussion with U.S. government agencies and other U.S.-based private sector companies.
- PRCo-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, GermanyCompany to engage with global customers and distributors while expanding international commercial relationshipsSALT LAKE CITY, April 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will participate in the Congress of the European Society of Clinical Microbiology and Infectious Disease ("ESCMID Global") 2026, taking place April 17-21 in Munich, Germany. ESCMID Global 2026 features academic and industry programming that
- PRCo-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC UtahTrade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS, Zurich Innovation Park and moreSALT LAKE CITY, April 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company executives will be participating in the latest World Trade Center (WTC) Utah trade mission with Utah Governor Cox and the Governor's Office of Economic Opportunity, taking place April 13-22 in locations across Switzerland and Germany.
CODX FAQ
7 questionsWhat does Co-Diagnostics Inc. do?
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant...Where does CODX stock trade?
Co-Diagnostics Inc. (CODX) is listed on NASDAQ.What sector and industry is CODX in?
Co-Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Co-Diagnostics Inc. go public?
Co-Diagnostics Inc. (CODX) completed its IPO in 2026.What are analysts saying about CODX?
Co-Diagnostics Inc. has had 3 recent analyst actions on file. The most recent action was from Sidoti: Neutral with a $500.00 price target on 2022-08-12. Recent price targets range from $500.00 to $1500.00.What companies are similar to CODX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare CODX side-by-side with any of them on Quantisnow.How can I track CODX on Quantisnow?
Quantisnow aggregates Co-Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CODX to receive live email and push alerts on every new disclosure.